Eve Health Group Limited · ASX:EVE
Eve Health — Merger or Acquisition (April 2025)
14 slides from Eve Health's merger presentation, Apr 14, 2025
Slide 1: Transformational Acquisition: Nextract
For personal use only TRANSFORMATIONAL ACQUISITION NEXTRACT REFORMULATING A PROVEN DRUG TARGETING THE $5.3B ERECTILE DYSFUNCTION MARKET ENHANCED SOLUBILITY DESIGNED FOR FASTER ACTION AND HIGHER EFFICACY © EVE HEALTH GROUP 2025
Slide 2: Important Notice and Disclaimer
For personal use only Important Notice and Disclaimer This presentation has been prepared by and issued by Eve Health Group Limited, to assist it in informing interested parties about the Company and its progress. It should not be considered as an offer or invitation to subscribe for or purchase any
Slide 3: Executive Summary
For personal use only Executive Summary Eve Health Overview: Eve Health Group specialises in innovative health solutions, enhancing patient care across various medical sectors. It currently owns Meluka Australia which targets gut health and generates approximately $2m in revenue in DTC sales. Nextra
Slide 4: Directors and Management
For personal use only Directors and Management DAMIAN WOOD Dr STUART GUNZBURG ROD HANNINGTON PROPOSED MANAGING CSO Non-Executive Chairman DIRECTOR Stuart has a PHD specialising in drug Rod has over 25 years of experience Damian is a registered industrial formulation and solubility science. His worki
Slide 5: The Market Demand for ED Solutions
The Market Demand for ED Solutions For personal use only 322m Phosphodiesterase 5 4 inhibitors (PDE5Is) are the first-line ED therapy. PDE5Is: Viagra, Cialis, Levitra Men globally are projected to be affected by erectile 60% -70% 2 dysfunction in 2025 40% 1 Patients report a positive outcome Men tha
Slide 6: The Nextract Product
The Nextract PRODUCT TIME TO EFFECTIVENESS For personal use only ED Solution Nextract 5 – 15 minutes1 Viagra 30 – 60 minutes (Sildenafil) Cialis 30 – 60 minutes (Tadalafil) Proprietary Solubility Technology: Nextract’s proprietary Levitra 25 – 60 minutes nanoemulsion platform is designed to enhance
Slide 7: Product Pipeline and Development Timeline
For personal use only Product Pipeline and Development Timeline ED Solution Product Product Stability FDA Bioequivalence Study Development 6 Months 6-9 Months Regulatory TGA (SAS-B)1 FDA Application 3 Months 3 - 6 Months Product Marketing Launch Production Product Sales Q1 2025 Q2 2025 Q3 2025 Q4 2
Slide 8: Path to Market
Path to Market For personal use only Regulatory Fast-Tracking in Australia: TGA access pathways for potentially faster commercialisation via (i) SAS-B1, (ii) Authorised Prescriber, (iii) ARTG Export Only. These frameworks enable expedited access for innovative therapies for unmet clinical need. Vita
Slide 9: The Nextract Product: Dysmenorrhea Solution
The Nextract PRODUCT TIME TO Dysmenorrhea Solution For personal use only EFFECTIVENESS Nextract 5 – 15 minutes2 NSAID (E.g. Ibuprofen, 30 – 60 minutes Naproxen) Addressable Market: Global market size of US$10.9b1 in 2024 Hormonal Contraceptives Several days to weeks Proprietary Solubility Technology
Slide 10: Transaction Structure and Indicative Timetable
For personal use only Transaction Structure and Indicative Timetable Pre-Consolidation Post-Consolidation1 Existing Shares 5,274,482,664 131,862,067 Vendor Shares 3,333,333,333 83,333,333 Placement Shares 1,111,111,120 27,777,778 Share Purchase Plan Shares2 555,555,547 13,888,889 Facilitation Shares
Slide 11: Investment Rationale
For personal use only Investment Rationale The purchase of Nextract will provide EVE with the capacity to quickly become a vertically integrated pharmaceutical and food manufacturer with a ready portfolio of health-related products. EXPEDITED MASSIVE SEAMLESS SIGNIFICANT SCALABLE PATH TO ADDRESSABLE
Slide 12: Sources and Uses of Funds
Sources and Uses of Funds For personal use only Sources of Funds A$m Placement 1.0 NEXTRACT - USE OF FUNDS Share Purchase Plan1 0.5 ED - A$0.3m Existing cash (as at 31 March 2025) 0.3 • Stability Testing Total Sources 1.8 • Regulatory Approval • Marketing/Production Uses of Funds A$m Dysmenorrhea -
Slide 13: About Meluka Australia
For personal use only About Meluka Australia Meluka Australia Overview: Meluka Australia is dedicated to delivering premium, taste-focused gut health solutions, leveraging the unique benefits of its proprietary Lactobacillus rhamnosus Beebiotic MAP01® strain. Meluka Australia delivers approximately
Slide 14: For personal use only
For personal use only 1/245 Churchill Ave, Subiaco WA 6008 +61 8 6465 5500 info@evehealthgroup.com.au W W W . E V E H E A L T H G R O U P . C O M . A U © EVE HEALTH GROUP 2025
Eve Health Group — Merger or Acquisition (April 2025) on 6ix